190 related articles for article (PubMed ID: 36810256)
1. SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis.
Xie Y; Sahin M; Wakamatsu T; Inoue-Yamauchi A; Zhao W; Han S; Nargund AM; Yang S; Lyu Y; Hsieh JJ; Leslie CS; Cheng EH
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810256
[TBL] [Abstract][Full Text] [Related]
2. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
3. Systematic
Walter DM; Venancio OS; Buza EL; Tobias JW; Deshpande C; Gudiel AA; Kim-Kiselak C; Cicchini M; Yates TJ; Feldser DM
Cancer Res; 2017 Apr; 77(7):1719-1729. PubMed ID: 28202515
[TBL] [Abstract][Full Text] [Related]
4. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
[TBL] [Abstract][Full Text] [Related]
5. Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
Zhu LY; Yuan JB; Zhang L; He CX; Lin X; Xu B; Jin GH
Cancer Res; 2022 Nov; 82(22):4153-4163. PubMed ID: 36098964
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
[TBL] [Abstract][Full Text] [Related]
7. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Zhang YL; Sun JW; Xie YY; Zhou Y; Liu P; Song JC; Xu CH; Wang L; Liu D; Xu AN; Chen Z; Chen SJ; Sun XJ; Huang QH
Cell Res; 2018 Apr; 28(4):476-490. PubMed ID: 29531312
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms in governing genomic stability and tumor suppression by the SETD2 H3K36 methyltransferase.
Lam UTF; Chen ES
Int J Biochem Cell Biol; 2022 Mar; 144():106155. PubMed ID: 34990836
[TBL] [Abstract][Full Text] [Related]
9. Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway.
Ma C; Liu M; Feng W; Rao H; Zhang W; Liu C; Xu Y; Wang Z; Teng Y; Yang X; Ni L; Xu J; Gao WQ; Lu B; Li L
Clin Transl Med; 2023 Nov; 13(11):e1475. PubMed ID: 37962020
[TBL] [Abstract][Full Text] [Related]
10. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A
Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333
[TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract][Full Text] [Related]
12. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
Arnal-Estapé A; Cai WL; Albert AE; Zhao M; Stevens LE; López-Giráldez F; Patel KD; Tyagi S; Schmitt EM; Westbrook TF; Nguyen DX
Oncogene; 2020 Apr; 39(18):3726-3737. PubMed ID: 32157212
[TBL] [Abstract][Full Text] [Related]
13. Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo.
Talluri S; Francis SM; Dick FA
PLoS One; 2013; 8(8):e72236. PubMed ID: 23936539
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.
Kato H; Tateishi K; Fujiwara H; Ijichi H; Yamamoto K; Nakatsuka T; Kakiuchi M; Sano M; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Otsuka M; Hirata Y; Tachibana M; Shinkai Y; Koike K
Cancer Genomics Proteomics; 2020; 17(6):695-705. PubMed ID: 33099471
[TBL] [Abstract][Full Text] [Related]
15. Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma.
Yang X; Chen R; Chen Y; Zhou Y; Wu C; Li Q; Wu J; Hu WW; Zhao WQ; Wei W; Shi JT; Ji M
Cancer Sci; 2022 Apr; 113(4):1195-1207. PubMed ID: 35152527
[TBL] [Abstract][Full Text] [Related]
16. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
17. Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription.
Carvalho S; Raposo AC; Martins FB; Grosso AR; Sridhara SC; Rino J; Carmo-Fonseca M; de Almeida SF
Nucleic Acids Res; 2013 Mar; 41(5):2881-93. PubMed ID: 23325844
[TBL] [Abstract][Full Text] [Related]
18. Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling.
Walter DM; Gladstein AC; Doerig KR; Natesan R; Baskaran SG; Gudiel AA; Adler KM; Acosta JO; Wallace DC; Asangani IA; Feldser DM
Commun Biol; 2023 Mar; 6(1):255. PubMed ID: 36899051
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.
Taparra K; Wang H; Malek R; Lafargue A; Barbhuiya MA; Wang X; Simons BW; Ballew M; Nugent K; Groves J; Williams RD; Shiraishi T; Verdone J; Yildirir G; Henry R; Zhang B; Wong J; Wang KK; Nelkin BD; Pienta KJ; Felsher D; Zachara NE; Tran PT
J Clin Invest; 2018 Nov; 128(11):4924-4937. PubMed ID: 30130254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
